| Methods |
Seven‐wk cross‐over trial; endpoints—"heart failure score," six‐minute walk test, CT ratio, QOL, LVED, FS, EX |
| Participants |
20 pts; mean age 63; 90% male; 50% Class II, 40% Class III; 90% on diuretics; prior dig Rx in 85%; dx—85% ischemic; valvular disease excluded |
| Interventions |
dig dosage titrated to serum level of 1.54 to 2.56 nmol/L (1.2 to 2.0 ng/mL), mean dig dosage 0.391 mg/d |
| Outcomes |
for dig versus pla, "heart failure score" 2.3 & 4.4 (P value 0.001), six‐minute walk test 411 & 392 m (P value 0.055), CT ratio 0.53 & 0.58 (P value 0.04), FS 21% & 17% (P value 0.04); no significant difference in QOL profile, LVED, EX |
| Notes |
blind allocation—yes
blinded to outcomes—yes
baselines comparable—NA
loss to follow‐up—?
dig titrated to level—yes |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Low risk |
A—Adequate |
